Inhibikase Therapeutics, Inc.
IKT
$1.66
-$0.01-0.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 107.64% | -406.34% | |||
| Gross Profit | -107.64% | 406.34% | |||
| SG&A Expenses | 8.88% | 20.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 217.70% | -56.76% | |||
| Operating Income | -217.70% | 56.76% | |||
| Income Before Tax | -28.63% | -6.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.63% | -6.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.63% | -6.74% | |||
| EBIT | -217.70% | 56.76% | |||
| EBITDA | -217.43% | 56.69% | |||
| EPS Basic | 7.67% | 22.26% | |||
| Normalized Basic EPS | -156.54% | 72.51% | |||
| EPS Diluted | 7.67% | 22.26% | |||
| Normalized Diluted EPS | -156.54% | 72.51% | |||
| Average Basic Shares Outstanding | 39.36% | 37.30% | |||
| Average Diluted Shares Outstanding | 39.36% | 37.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||